Sandoz launches first, only biosimilar for RRMS called Tyruko in Germany

Sandoz announces the launch of Tyruko in Germany from February 1. Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat relapsing remitting multiple sclerosis, RRMS. Tyruko is indicated as a single disease-modifying therapy in adults with highly active RRMS. This is the same indication as approved by the European Commission for reference medicine Tysabri. Rebecca Guntern, President Europe, Sandoz, said: “Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future disabilities. As the first and only biosimilar in this space, the availability of Tyruko is a crucial milestone in improving access to effective and safe therapies for those in Europe that need them most.”